FirebrickPharma

INVESTOR PRESENTATION
11 MARCH 2022

EUROZ HARTLEYS ROTTNEST ISLAND INSTITUTIONAL CONFERENCE

IMPORTANT NOTICE AND DISCLAIMER

This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared as of its date, and remains subject to change without notice. This presentation has been provided to you solely for the purpose of giving you background information about Firebrick Pharma Limited (**Firebrick**). This presentation is intended only for those persons to whom it is delivered personally by or on behalf of Firebrick. By attending this presentation, you represent and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document (as defined in the Corporations Act 2001 (Cth) (**Corporations Act**)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are outside Australia, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this document and any copies and do not provide this document to any other person. This presentation is strictly confidential and is intended for the exclusive benefit of the person to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of Firebrick. The recipient shall not disclose any of the information contained in this presentation to any other person without the prior written consent of Firebrick, which may be withheld in its absolute discretion.

No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. Neither Firebrick, its related bodies corporate, shareholders or affiliates, nor any of their respective officers, directors, employees, related bodies corporate, affiliates, agents or advisers makes any representations or warranties that this presentation is complete or that it contains all material information about Firebrick or which a prospective investor or purchaser may require in evaluating a possible investment in Firebrick or an acquisition of its shares. To the maximum extent permitted by law, none of those persons accept any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based upon information known and assumptions made as of the date of this presentation. Forward looking statements can generally be identified by the use of forward looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, and guidance or outlook on, clinical trials, required regulatory approvals, future earnings or financial position or performance are also forward looking statements. These statements are subject to internal and external risks and uncertainties that may have a material effect on future business. Actual results may differ materially from any future results or performance expressed, predicted or implied by the statements contained in this presentation. As such, undue reliance should not be placed on any forward looking statement. Past performance is not necessarily a guide to future performance. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future. No person is under any obligation to update this presentation at any time after its release to you.

The provision of this presentation is not a representation to you or any other person that an offer of securities will be made. Any prospective transaction would be undertaken solely on the basis of disclosure documentation prepared in accordance with applicable securities laws and regulations. The information presented in this presentation may differ materially in both content and presentation from that presented in any disclosure document prepared in connection with any prospective transaction. Firebrick reserves the right to alter the information contained in this presentation in any disclosure document prepared in respect of any prospective transaction from the form of this presentation accordingly.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in Firebrick and neither this presentation nor any of the information contained herein shall form the basis of any contract or commitment. In particular, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

This presentation may not be reproduced or redistributed to any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party without the prior approval of Firebrick. All references to dollars, cents or $ in this presentation are to Australian currency, unless otherwise stated.

In receiving this presentation, each recipient agrees to the foregoing terms and conditions.

FIREBRICK IPO STORY

Australian Pharmaceutical Innovator Focused on Infectious Disease

Breakthrough Product: Nasodine

- Kills[1] the viruses that cause colds
- First-in-class nasal spray medicine that targets the viral cause of the common cold
- Acts in the nose, where colds start

Same active as BETADINE® products[2]

- Povidone-iodine (PVP-I) widely used as a gargle, now in a nasal spray, Nasodine® Nasal Spray
- Patent protected to 2034/2035 as a treatment or preventative for common cold

Pandemic Potential

- Kills SARS-CoV-2 *in vitro*
- Phase 2 COVID-19 clinical trial in 2022
- US Patent granted for use in COVID-19

Late-stage Biopharma story

- Nasodine completed Phase 1-3 trials
- Second Phase 3 trial in 2022
- Manufacturing ready
- Potential near-term regulatory approval

Large Addressable Market

- Global potential
- Billions of colds each year worldwide
- Potential for broad market adoption

Proven Successful Team

- Firebrick founder launched Betadine® Gargle[2]
- Track record of success on ASX
- Experienced management and board

[1] For viruses, the term "kill" indicates elimination of viral infectivity. In *in vitro* studies, Nasodine has been shown to eliminate the infectivity of representative strains of all viruses known to cause respiratory infections, such as the common cold.

[2] Betadine® is a registered trademark of Mundipharma AG and in Australia is now licensed to Sanofi Aventis. There is no association between Firebrick, Mundipharma, Sanofi Aventis or the Betadine brand. Povidone-iodine is widely available and can be supplied and used without license from Mundipharma or any other party.

IPO PERFORMANCE

Listed on ASX as ‘FRE’ on 28 January 2022

Extensive media coverage

28 Jan 2022

Firebrick launch on ASX receives national media attention

High performance in bear market

- IPO: $0.20 x 169m shares = $34m m/cap
- 52 million shares traded in first 5 days
- 5-day VWAP to 8 March = $0.43
  still up >100% on IPO price; m/cap ~ $70m
- Shareholders increased from 400 -> 4,600

The Firebrick appeal

- Many early investors were Australian doctors who believe in the product concept
- Technology story is easy to comprehend: *kills viruses in the nose to treat colds*
- Unprecedent public awareness of the role of viruses in respiratory illness
- The common cold is a huge global market – first nasal spray medicine targeting viral cause
- Perceived low risk Phase 3 trial with potential for near-term approval
- Upside of potential COVID-19 use and role in future pandemics
- Management calibre & track record on ASX
- Support of Euroz Hartleys – sole Lead Manager

NASODINE PACKAGING AS SUBMITTED TO TGA

NASODINE® NASAL SPRAY

- **Australian breakthrough** that could be the world's first approved nasal medicine that actually **targets the viral cause** of colds
- **Contains povidone-iodine (PVP-I) 0.5%**
  - In a proprietary formulation, safe for use on nasal tissue[1]
- **Kills[2] all respiratory viruses**
  - PVP-I releases free iodine that kills all respiratory viruses
  - Virucidal – leads to permanent loss of viral infectivity
  - Non-selective – viral resistance has not been reported to PVP-I
- **Strong patent position; granted patents in the U.S, EU, AU + others**
  - Protect use of intranasal PVP-I as treatment/preventative for common cold (2034/35) and use in pandemic viral diseases (2040)
- **Nasodine® Nasal Spray ("Nasodine") is not yet approved for sale**
  - 2nd Phase 3 trial planned for 2022 prior to re-submission to TGA
  - Potential for approval in 2022 if Section 60 appeal succeeds

[1] At low concentrations (e.g., 0.5%) and in an appropriate formulation

[2] For viruses, the term "kill" indicates elimination of viral infectivity. In *in vitro* studies, Nasodine has been shown to eliminate the infectivity of representative strains of all viruses known to cause respiratory infections, such as the common cold.

Nasodine's Initial Indication: The COMMON COLD in adults

- **Large addressable market**
  - 2.5 billion colds annually in US and Europe[1] (60 million in AU)
  - High economic cost in lost productivity, doctor visits and medications[1]
  - COVID has elevated viral infectious disease as a therapeutic priority
- **Colds are caused by viruses**
  - The viral infection starts in the nose
  - It's a superficial infection of the nasal cells, despite the systemic symptoms
- **Colds are very difficult to treat**
  - Antibiotics don't work against viruses
  - Colds can be caused by up to 200 different viruses[1]
  - Needs a broad-spectrum solution – like Nasodine® Nasal Spray



[1] IQVIA Industry and Market Overview report 2021

THE NASODINE® BREAKTHROUGH

A cold begins when a virus infects the cells lining the nasal passages

Nasodine® Nasal Spray disperses through the nasal passages to target the viruses that cause the infection

EXISTING COLD TREATMENTS TARGET SYMPTOM RELIEF ONLY

- Temporary relief of symptoms
  - Sore throat
  - Runny nose
  - Cough
  - Allow the sufferer to “soldier on”
- No impact on the viral cause of colds

NASODINE NASAL SPRAY TARGETS THE VIRAL CAUSE OF COLDS

- Nasodine (if approved) will be the world’s first approved nasal spray medicine that kills the viruses that cause colds
- 1st Phase 3 trial showed that Nasodine reduces overall cold severity (in key subsets) and impact of colds on daily activities in all subjects.

COMMON COLD MARKET OPPORTUNITY

THE PRODUCT

- Dosage for common cold treatment is:
  3 sprays per nostril, 4 times daily for 5 days
- Each **25ml bottle** contains **30 doses**
  (20 doses needed for each cold)
- Expected retail price is **AU$24** [1]
  (once approved) sold in **pharmacies only**
- **Market research** suggests strong support for Nasodine from GPs and pharmacists[2]
- **Nasodine is a consumer product** that may be used regularly by everyday Australians (potential shareholders in FRE)

THE OPPORTUNITY

US$40 billion economic cost of colds in U.S. alone

60 million adult colds in Australia per year

2.5 billion colds in U.S. & Europe per year[3]

[1] Estimated retail pricing, subject to change

[2] IQVIA 2021 survey of 200 Australian GPs and 200 Australian pharmacists

[3] IQVIA Industry and Market Overview report 2021

MANUFACTURING READY, PARTNERSHIP AGREEMENTS IN PLACE

AUSTRALIA

- Firebrick to market all its products **directly in Australia**
- Management has experience in building sales and marketing organisations, and in launching and marketing OTC products in Australia
- **Manufacturing ready:** All packaging, formulation and process development completed. Exclusive manufacturing and supply agreement with Probiotec (ASX: PBP) in Laverton North VIC

GLOBAL

- Outside Australia, licensed distributors to be used. **Agreements already in place** in Philippines, New Zealand and Sub-Saharan Africa, where Firebrick is to receive a royalty on sales
- Partnerships in Europe and US likely to be pursued once Phase 3 trial completed
- Management has experience in international licensing and distribution, and board with US/global reach

PATHWAY TO APPROVAL

- Initial registration dossier submitted to TGA in 2020:
  - Nasodine met all manufacturing, quality and safety hurdles
  - But TGA decided that clinical efficacy was not satisfactorily established by the first Phase 3 trial, because the positive result on the selected primary endpoint (nasal symptoms) was not statistically significant
- However, Nasodine did have a significant positive impact on **quality-of-life** (impact of the cold on daily life) in all subjects, and **overall cold severity** in key subsets:
  - Those with **stronger cold symptoms**
  - Those with **confirmed viral infections**
  - Those who started **treatment early** (<24 hours after 1st symptoms)
- Firebrick believes the trial results do support approval and is currently appealing the initial decision by TGA; if successful (result by end July 2022), Nasodine could be approved in 2022
- In parallel, Firebrick will conduct a second Phase 3 trial during 2022 to support approval in Australia (if the appeal is unsuccessful)
- Trial results also expected to be needed for registration filings in Europe and U.S. (input to trial design received from EMA and FDA)
- Trial expected to begin **before May 2022; headline results expected in Q4 CY2022**

KEY FEATURES	2022 PHASE 3 TRIAL
Primary endpoint	Overall cold severity (GSS) (validated endpoint of WURSS-21)
Population for primary endpoint assessment	People with confirmed viral colds (based on nasal swabs and PCR)
Inclusion criteria (differences)	Early symptoms only (< 36 hours after onset)
	People with stronger symptoms
Trial design	Randomised, controlled, confirmatory Phase 3 trial in 196 adults with viral colds

FUTURE OPPORTUNITIES

COMMON COLD PREVENTION

- Subject to further clinical trials Nasodine could be approved for prevention of colds



REDUCING HOSPITAL INFECTION RISK BY PPB

- Nasodine could be used in hospitals to decolonize the nasal passages of staff and patients
- Goal: eliminate MRSA and other bacteria to reduce surgical site infection risk



COVID-19 & FUTURE PANDEMICS

- Nasodine is effective *in vitro* against SARS-CoV-2 and reduced viral shedding in pilot human study for up to one hour post-dose
- COVID-19 Phase 2 trial to start in 2022

PRODUCT DEVELOPMENT

- Several new products in development beyond Nasodine Nasal Spray

COVID-19
PHASE 2 CLINICAL TRIAL

- Randomised controlled Phase 2 trial in South Africa of Nasodine in COVID-19 patients
- Subjects: 144 adults who will be confirmed to be actively shedding SARS-CoV-2
- Goal: Demonstrate that frequent doses of Nasodine significantly reduces nasal shedding
- SAHPRA and HREC approvals in place; patient recruitment to start soon with results expected in Q3 CY22
- If Nasodine reduces or eliminates viral shedding, it could potentially reduce the risk of transmission and/or reduce isolation period for those with COVID-19
- Results may point to role of Nasodine in future pandemics, with potential for pandemic stockpiling as first line of defence

STUDY ENDPOINT

Nasodine application 8 times daily (every 2 hours) for 2.5 days significantly reduces nasal shedding of SARS-CoV-2 [compared with placebo nasal spray]

OTHER OBJECTIVES

- Reduces the number of days to a negative RAT
- Accelerates clearance of SARS-CoV-2 from nose and throat
- Beneficial impact on symptoms of COVID-19

OUTSTANDING BOARD WITH GLOBAL REACH AND EXPERIENCE

PETER MOLLOY

FOUNDER
EXECUTIVE CHAIRMAN

BSc, MBA, PhD, FAICD

Microbiologist & biochemist who built the Betadine OTC franchise, launched Betadine® Sore Throat Gargle.

General Manager Faulding Medical Products; President Faulding (USA) Inc.; Managing Director Pharmacia Australia; Vice President Strategic Marketing Pharmacia (USA).

Launched 23 products, executed 40 international licensing/distribution deals.

CEO of two leading ASX biotechs:

- Biota (BTA) 2002-05; m/cap grew from $30m to $300m;
- Race Oncology (RAC) 2016-20; listed at $11m, currently ~$400m

---

PhD in business: Investor performance in the Australian biotech sector

STEPHEN GOODALL

CO-FOUNDER
DIRECTOR, COO

BAppSc, MAppSc, MBA, PhD

PhD chemist, co-founder and co-inventor on Firebrick patents. Developer of Nasodine formula.

Previously, was Chief Operating Officer of Viralytics (later acquired in 2018 for $500 million by Merck), Director of Pharmaceutical Development at Vapotronics, Director of Development at AGEN Biomedical.

Hands-on experience in all phases of development and manufacturing of pharmaceuticals.

PHYLLIS GARDNER

NON-EXECUTIVE
DIRECTOR

MD (Harvard)

Phyllis Gardner MD is Professor of Medicine at Stanford University and on the Board of Fellows of Harvard Medical School.

Obtained her MD from Harvard Medical School, trained in internal medicine at Mass. General Hospital and post-doc fellowships in Pharmacology at Columbia University and University College, London.

Former Head of Research at ALZA Corporation and Partner at leading US VC firm, Essex Woodlands.

Director on boards of multiple US public biotech firms.